Halozyme Therapeutics, Inc. (NASDAQ: HALO) Receives an Average “Moderate Buy” Rating from Brokerages
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO – Get Rating) earned a consensus “moderate buy” recommendation from the eight brokerages that cover the company, Marketbeat Ratings reports. One investment analyst gave the stock a hold rating and six gave the company a buy rating. The 12-month average price target among brokerages that have covered the stock over the past year is $52.00.
A number of research companies have recently commented on HALO. Morgan Stanley began covering Halozyme Therapeutics shares in a research note on Friday, September 9. They set an “overweight” rating and a target price of $50.00 for the company. StockNews.com began covering Halozyme Therapeutics shares in a research note on Wednesday, October 12. They set a “hold” rating for the company.
Hedge funds weigh in on Halozyme Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. William Blair Investment Management LLC increased its stake in Halozyme Therapeutics by 5.2% in the 1st quarter. William Blair Investment Management LLC now owns 5,339,891 shares of the biopharmaceutical company valued at $212,955,000 after purchasing an additional 266,226 shares in the last quarter. Macquarie Group Ltd. increased its stake in Halozyme Therapeutics by 1.9% in the second quarter. Macquarie Group Ltd. now owns 2,520,531 shares of the biopharmaceutical company valued at $110,903,000 after purchasing an additional 45,885 shares in the last quarter. Loomis Sayles & Co. LP increased its stake in Halozyme Therapeutics by 13.4% in the 1st quarter. Loomis Sayles & Co. LP now owns 2,185,274 shares of the biopharmaceutical company valued at $87,149,000 after purchasing an additional 257,536 shares in the last quarter. Victory Capital Management Inc. increased its equity stake in Halozyme Therapeutics by 206.7% in Q2. Victory Capital Management Inc. now owns 1,790,044 shares of the biopharmaceutical company worth $78,761,000 after acquiring 1,206,368 additional shares in the last quarter. Finally, GW&K Investment Management LLC increased its stake in Halozyme Therapeutics shares by 6.1% in the 1st quarter. GW&K Investment Management LLC now owns 1,653,859 shares of the biopharmaceutical company worth $65,956,000 after acquiring 95,215 additional shares in the last quarter. 91.72% of the shares are currently held by institutional investors and hedge funds.
Halozyme Therapeutics trades down 1.0%
Shares of Halozyme Therapeutics opened at $46.59 on Friday. The company has a 50-day simple moving average of $42.43 and a two-hundred-day simple moving average of $44.06. The company has a market capitalization of $6.42 billion, a P/E ratio of 18.42, a price-to-earnings growth ratio of 0.90 and a beta of 1.22. Halozyme Therapeutics has a fifty-two week low of $31.36 and a fifty-two week high of $52.98. The company has a debt ratio of 3.91, a quick ratio of 2.23 and a current ratio of 2.72.
Halozyme Therapeutics Inc (NASDAQ:HALO – Get Rating) last released quarterly earnings data on Tuesday, August 9. The biopharmaceutical company reported earnings per share of $0.50 for the quarter, beating analysts’ consensus estimate of $0.47 by $0.03. The company posted revenue of $152.37 million in the quarter, versus a consensus estimate of $156.00 million. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The company’s revenue increased by 11.7% compared to the same quarter last year. In the same quarter a year earlier, the company posted earnings per share of $0.63. As a group, stock analysts predict Halozyme Therapeutics will post earnings per share of 1.93 for the current fiscal year.
Halozyme Therapeutics Company Profile
(Get an assessment)
Halozyme Therapeutics, Inc operates as a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan and internationally. The Company’s products are based on ENHANZE drug delivery technology, a patented recombinant human hyaluronidase (rHuPH20) enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. , as well as small molecules and fluids.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Halozyme Therapeutics, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Halozyme Therapeutics didn’t make the list.
Although Halozyme Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here